Tag Archives: NASDAQ:ADVM
Cowen & Co. Maintains Their Buy Rating on Adverum Biotechnologies (ADVM)
In a report released today, Phil Nadeau from Cowen & Co. maintained a Buy rating on Adverum Biotechnologies (ADVM – Research Report). The company’s shares closed last Monday at $7.94. According to TipRanks.com, Nadeau is a 5-star analyst with an
Chardan Capital Sticks to Its Hold Rating for Adverum Biotechnologies (ADVM)
Chardan Capital analyst Gbola Amusa reiterated a Hold rating on Adverum Biotechnologies (ADVM – Research Report) today and set a price target of $10. The company’s shares closed last Monday at $12. Amusa observed: “We note the “positive” OPTIC results
Adverum Biotechnologies (ADVM) Gets a Hold Rating from Chardan Capital
Chardan Capital analyst Gbola Amusa reiterated a Hold rating on Adverum Biotechnologies (ADVM – Research Report) today and set a price target of $10. The company’s shares closed last Monday at $13.40. According to TipRanks.com, Amusa is a 5-star analyst
Cowen & Co. Believes Adverum Biotechnologies (NASDAQ: ADVM) Still Has Room to Grow
In a report released today, Phil Nadeau from Cowen & Co. maintained a Buy rating on Adverum Biotechnologies (ADVM – Research Report). The company’s shares closed yesterday at $14.90, close to its 52-week high of $14.96. According to TipRanks.com, Nadeau
Adverum Biotechnologies (ADVM) Receives a Buy from Cowen & Co.
Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Adverum Biotechnologies (ADVM – Research Report) today. The company’s shares opened today at $6.48. According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 6.7% and
Why Did Cantor Fitzgerald Downgrade Adverum Biotechnologies’ Stock?
Cantor Fitzgerald analyst Charles Duncan downgraded Adverum Biotechnologies (ADVM) to Hold yesterday and set a price target of $4. The company’s shares closed on Friday at $3.34, close to its 52-week low of $2.62. Duncan observed: “. We are downgrading
